Piperazine

Piperazine

SCHEMBL5875381

C1CNCCN1.O=[N+]([O-])O

nearest known ligand 0.57

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ESR1

The experimentally established mechanism targets of Piperazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CA5A P35218 1/20 0.57
CA5B Q9Y2D0 1/20 0.57
HIF1A Q16665 1/20 0.43
MAPT P10636 1/20 0.43
PDE4A P27815 1/20 0.43
KDR P35968 1/20 0.43
CXCR4 P61073 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
ADRB1 P08588 1/20 0.32
SIRT6 Q8N6T7 1/20 0.32
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
KDM4E B2RXH2 1/20 0.30
GAA P10253 1/20 0.30
CYP2C9 P11712 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Piperazine SCHEMBL14695887 1.00 CA5A (0.57) CA5ACA5BHIF1AMAPTPDE4A
Nitric Acid SCHEMBL11794277 1.00 CA5A (0.57) CA5ACA5BHIF1AMAPTPDE4A
Nitric Acid SCHEMBL6680089 0.96
Pyrrolidine SCHEMBL4890817 0.87
Piperidine SCHEMBL5874511 0.84 ALDH1A1 (0.53) CA5ACA5BCXCR4SMN1; SMN2
SCHEMBL8505448 0.81 HIF1A (0.46) CA5ACA5BHIF1AMAPTPDE4A
SCHEMBL8904167 0.81 HIF1A (0.46) CA5ACA5BHIF1AMAPTPDE4A
Piperazine SCHEMBL28852777 0.81 HIF1A (0.46) CA5ACA5BHIF1AMAPTPDE4A
Nitric Acid SCHEMBL5173170 0.80
Nitric Acid SCHEMBL11606188 0.80 CA5A (0.89) CA5ACA5BHIF1AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116478046-B Method for preparing tertiary amine by taking secondary amine as raw material 浙江新化化工股份有限公司 2025-03-07 CN disclosed
CN-119242181-A Polishing solution with low roughness and high removal amount and preparation method and application thereof 宁波平恒电子材料有限公司 2025-01-03 CN disclosed
US-20240228449-A1 METHOD FOR PREPARING TERTIARY AMINE WITH SECONDARY AMINE AS RAW MATERIAL ZHEJIANG XINHUA CHEMICAL CO., LTD (CN) 2024-07-11 US disclosed
EP-4324820-A1 METHOD FOR PREPARING TERTIARY AMINE BY USING SECONDARY AMINE AS RAW MATERIAL Zhejiang Xinhua Chemical Co., Ltd. (CN) 2024-02-21 EP disclosed
CN-116478046-A Method for preparing tertiary amine by taking secondary amine as raw material 浙江新化化工股份有限公司 2023-07-25 CN disclosed
WO-2023134439-A1 METHOD FOR PREPARING TERTIARY AMINE BY USING SECONDARY AMINE AS RAW MATERIAL 浙江新化化工股份有限公司 2023-07-20 WO disclosed
CN-104341424-B The method of ionic liquid-catalyzed nitrated synthesis TNAD 南京理工大学 2016-07-06 CN disclosed
CN-102614179-B As be used for the treatment of cognitive impairment, 1-[2-(2, the 4-dimethylphenylsulfanyl)-phenyl] piperazine of the compound to serotonin reabsorption, 5-HT3 and 5-HT1A activity with combination H. LUNDHECK A/S (DK) 2015-11-25 CN disclosed
CN-102617513-B As be used for the treatment of cognitive impairment, 1-[2-(2, the 4-dimethylphenylsulfanyl)-phenyl] piperazine of the compound to serotonin reabsorption, 5-HT3 and 5-HT1A activity with combination H. LUNDHECK A/S (DK) 2015-09-23 CN disclosed
CN-104341424-A Method for synthesizing TNAD through catalytic nitration by using ionic liquid UNIV NANJING SCIENCE & TECH 2015-02-11 CN disclosed
CN-103948597-A Use of 1- [2- (2, 4-dimethylphenylsulfanyl) phenyl ] piperazine for the treatment of pain or residual symptoms of depression associated with sleep and cognition LUNDBECK & CO AS H 2014-07-30 CN disclosed
CN-102614179-A 1- [2- (2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment LUNDBECK & CO AS H 2012-08-01 CN disclosed
CN-102617513-A 1- [2- (2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 AND 5-HT1A activity for the treatment of cognitive impairment LUNDBECK & CO AS H 2012-08-01 CN disclosed
CN-101472906-B 1- [2- (2, 4-dimethylphenylsulfanyl) -phenyl ] piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment LUNDBECK & CO AS H 2012-04-25 CN disclosed
CN-101636161-A 1- [ 2- (2, 4-dimethylphenylsulfanyl) phenyl ] piperazine as a compound with combined 5-hydroxytryptamine reabsorption, 5-HT 3 and 5-HT 1A activity for the treatment of pain or residual symptoms of depression associated with sleep and cognition LUNDBECK & CO AS H 2010-01-27 CN disclosed
US-7128976-B2 Composition for film formation, method of film formation, and silica-based film JSR CORPORATION (JP) 2006-10-31 US disclosed
US-20030091838-A1 Composition for film formation, method of film formation, and silica-based film JSR CORPORATION (JP) 2003-05-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240228449-A1 METHOD FOR PREPARING TERTIARY AMINE WITH SECONDARY AMINE AS RAW MATERIAL OTC, AOC1, ODC1 CA5A 199/4885CA5B 146/4885HIF1A 2242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.